CXCR3 and neoplasm: Thus, in addition to improved effector T-cell activity, another mechanism behind successful Treg-targeted immunotherapy may be to enhance the levels of CXCR3 ligands locally available in tumors, which in turn might increase the recruitment of cells with potent anti-tumor effector functions.